Using Nanotechnology, European Research Consortium To Create New Vaccine for Hepatitis C

Jul 05, 2011

Joint project HCVAX includes university and corporate research teams from Germany, France and Switzerland

Current treatments for Hepatitis C are expensive and have severe side effects. Approximately 3% of the European population has been affected by the virus. The researchers plan to use biocompatible nanogels as novel drug amplifiers, targeting virus Hepatitis C more effectively and with minimal side effects to the patient. Funding for the project is coming from the European Union’s EuroNanoMed Joint Transnational Initiative.

↑ Back to Nano World News™